Skip to main content

Table 5 Mean changes from baseline to week 52 in all PROs, reported by patients with ≤ 5%, > 5 to ≤ 10%, or > 10% decline in FVC % predicted over the study period (analysis 1)

From: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

 Mean change from baseline to week 52
≤ 5% decline in FVC>  5 to ≤ 10% decline in FVC>  10% decline in FVC
SGRQ total score−0.18 (n = 477)4.84** (n = 194)13.10***, ‡ (n = 152)
SGRQ symptom score−2.39 (n = 492)7.46*** (n = 198)9.40*** (n = 155)
SGRQ activity score0.78 (n = 486)5.75** (n = 196)15.58***, ‡ (n = 154)
SGRQ impacts score0.28 (n = 482)4.02* (n = 198)13.15***, ‡ (n = 153)
UCSD-SOBQ3.02 (n = 441)7.65** (n = 176)15.85***, † (n = 132)
CASA-Q cough symptom scorea2.47 (n = 495)−3.90** (n = 201)−5.27*** (n = 155)
CASA-Q cough impact scorea1.38 (n = 495)−6.48*** (n = 200)−8.59*** (n = 156)
EQ-5D VASa−0.69 (n = 490)−4.78** (n = 197)−10.83***, † (n = 151)
  1. CASA-Q cough and sputum assessment questionnaire (symptom and impact score), EQ-5D VAS EuroQoL 5-dimensional quality of life questionnaire visual analog scale, FVC forced vital capacity, PRO patient-reported outcome, SGRQ St George’s respiratory questionnaire (total, symptoms, activity and impacts score), UCSD-SOBQ University of California San Diego shortness of breath questionnaire
  2. *P < 0.05; **P < 0.01; and ***P < 0.0001 vs the group with ≤ 5% decline in FVC
  3. P < 0.01 and P < 0.0001 vs the group with > 5 to ≤ 10% decline in FVC
  4. aDecrease in score indicates worsening health